Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
The trend is especially severe for high-impact therapies like GLP-1 drugs for weight loss and diabetes, where denial rates reached 85% in some plans
Another 2025 survey published in JAMA Health Forum noted that, should Medicare pay for the drugs, it could avoid spending a hypothetical $18.2 billion on obesity-related health expenditures over 10 years while dishing out $65.9 billion annually on the GLP-1s by year 10, thereby negating any savings
Endocrine markers Baseline concentrations of the endocrine markers at T1 were not significantly different across the four conditions ( p s 0.05, Table S2)
Our results showed that LCLT supplementation was safe and well tolerated, and may be protective, since we found a decrease in coagulation disturbance markers, as well as reduction in the severity of lung alterations when given to patients with mild COVID-19 (Cohort 2)
US$ 27.87
US$ 21.34
US$ 24.53
US$ 27.81
US$ 20.56
US$ 29.33
US$ 23.13
